Dr. Reddy’s Projects 50% Growth In U.S. OTC Business

The Indian private labeler predicts annualized U.S. OTC sales of $200 million by March 2013. Dr. Reddy’s recently launched an equivalent of Allegra-D 24 Hour and plans to introduce generic Prevacid 24HR in its next fiscal year.

Dr. Reddy's Laboratories Ltd. plans to grow significantly in the U.S. private-label OTC drug market, with an eye toward chipping away at Perrigo Co. PLC’s lead in the segment.

The Indian firm predicts that by the end of its next fiscal year in March 2013 its U.S

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America